Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma

#13

Introduction: Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis, many of them are already advanced and difficult to treat.

Aim(s): We tried to perform a downstaging of a primary inoperable pancreatic neuroendocrine tumor to reach operability.

Materials and methods: We report on an initially inoperable malignant pancreatic endocrine tumor in a 33-year-old woman who received neoadjuvant peptide receptor radionuclide therapy (PRRT) as first-line treatment.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Kaemmerer D, Vikas P, Daffner W, Hörsch D, Klöppel G,

Keywords: endocrine pancreatic carcinoma, peptide receptor radionuclide therapy, neodjuvant treatment, pancreatic surgery, molecular imaging, receptor PET/CT,